RT Journal Article
SR Electronic
T1 Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6393
OP 6397
DO 10.21873/anticanres.12999
VO 38
IS 11
A1 KALLE MATTILA
A1 PIRITA RAANTA
A1 VALTTERI LAHTELA
A1 SEPPO PYRHÖNEN
A1 ILKKA KOSKIVUO
A1 PIA VIHINEN
YR 2018
UL http://ar.iiarjournals.org/content/38/11/6393.abstract
AB Background: Immune checkpoint and serine/threonine-protein kinase inhibitors have become a standard of care for advanced cutaneous melanoma, but dacarbazine-based chemotherapies are occasionally used. This study assessed the long-term efficacy of chemoimmunotherapy (bleomycin, vincristine, lomustine and dacarbazine with/without subcutaneous interferon-alpha: BOLD–INF-α) as real-world data in patients with metastatic melanoma not eligible for clinical trials. Patients and Methods: Medical data of 146 patients with stage IV melanoma who had received BOLD/BOLD–INFα regimen during 1991-2010 were analyzed. Results: The median overall survival was 8.9 months (95% confidence intervaI=7.5-10.4 months). The 1-year survival rate was 36%, 2-year 18%, and 5-year 13%. The 5-year survival rates in the M1a, M1b and M1c subgroups were 28%, 10% and 6%, respectively. Overall, 7% (n=11) of the patients were alive at the end of the follow-up. Conclusion: Our study showed similar overall survival among patients with stage IV cutaneous melanoma treated with BOLD/BOLD–INFα as noted previously with chemotherapy.